Inhaler monitoring company Adherium has announced the appointment of Francis White as VP of Global Business Development. White was most recently Managing Director of Olympus Medical in the UK and Ireland and previously held business development roles at AliveCor and Medtronic. Adherium’s next generation Hailie inhaler sensor platform received 501(k) clearance in September 2021, and the company recently submitted a 501(k) for a new Hailie sensor for use with Ellipta DPIs.
White commented, “I couldn’t be more excited to bring our brand new, revolutionary, data-rich, digital Inhaler platform to new and existing pharmaceutical and CRO customers across the world. This industry leading physiological sensing technology brings the potential to surface unprecedented, and previously unattainable, insights and novel outcome measures. A new strategy engaging at customer senior management levels will expand our partnerships and reach enabling us to power many more effective clinical trials and at the same time, help meet carbon reduction targets.”
Adherium CEO Rick Legleiter said, “The UK is home to global leaders in respiratory medications and therapeutics and Francis joining our leadership team is a key staffing milestone for a new strategic sales approach to acquiring new customers while supporting current customers to grow revenue in this market segment. With so much non-COVID-19 clinical trial work stopped or put on hold due to pandemic workload, lack of hospital access, and difficulty recruiting participants, we expect a continued resurgence to pre-pandemic levels globally. Given the Company’s historical experience, now is the time to leverage our digital platform including our new, next generation digital inhalers with physiological parameters offering an unmatched value proposition to clinical partners that has never been stronger.”
Read the Adherium press release.
